

Performance Strategies for The Supportive Management of Acute Respiratory Distress Syndrome (ARDS): A Review Paper

Dauda Danladi¹, Ndubuka G. Ihebuzo ² and L.U Ezeamaku³

1 Department of Biomedical Engineering, Federal University of Technology Owerri, Nigeria.
FUTO, Nigeria 1; eldauda@yahoo.com

2 Department of Biomedical Engineering, Federal University of Technology Owerri, Nigeria.
FUTO, Nigeria 2; chiomaimmenmachi@gmail.com

3 Department of Biomedical Engineering, David Nweze Umahi University of Medical Science,
Uburu, Ebonyi State, Nigeria 3
Correspondence: eldauda@yahoo.com;

doi: <https://doi.org/10.37745/ejbmsr.2013/vol14n419>

Published August 23, 2026

Citation: Danladi D., Ihebuzo N.G. and Ezeamaku L.U. (2026) Performance Strategies for The Supportive Management of Acute Respiratory Distress Syndrome (ARDS): A Review Paper, *European Journal of Biology and Medical Science Research*, 14(4),1-9

Abstract: *Acute Respiratory Distress Syndrome (ARDS) is a serious lung disease in which inadequate ventilation of the lungs makes it difficult for oxygen to pass through into the body, the lungs are too stiff, and there are complex interactions between their physiology and the mechanical support they receive. Ventilator settings, ventilator responses, oxygen delivery and monitoring performance must be continually assessed in order to implement supportive management. The review will explore recent advances in mathematical respiratory modelling, lung protective ventilation, real-time graphical visualization, Web based monitoring, oxygen delivery and intensive care monitoring technologies useful for supportive care of ARDS. The examined literature shows many progresses in specific parts, but not so much in integrating them into a unified computational framework. In particular, physiological modelling, optimization of ventilator parameters, respiratory waveforms, remote monitoring and assessment of equipment performance are emphasized. The review highlights the requirement for an integrated ARDS specific simulation and monitoring environment that will enable a connection of ventilator inputs and dynamic physiological responses. The integration may be used to aid in research, education, training, and biomedical engineering evaluation, and can be used to create a controlled environment for research of supportive respiratory management strategies.*

Keywords: ARDS, mechanical ventilation, lung-protective ventilation, lung mechanics, mathematical modelling, computational simulation.

INTRODUCTION

ARDS is a heterogeneous acute respiratory failure syndrome caused by inflammatory pulmonary injury that disrupts the alveolar–capillary barrier leading to decreased functional aerated lung volume and compromising oxygen transfer. The clinical challenge is not just to deliver more oxygen but to preserve a good balance of gas exchange with minimum additional mechanical injury. Nowadays, lung protection, personalized respiratory assistance and ongoing evaluation of the patients' condition are at the heart of their care [1].

Mechanical ventilation continues to be a mainstay of supportive care in the management of those who are unable to maintain adequate ventilation or oxygenation. Evidence indicates that the tidal volume should be lower, and plateau pressures should be limited; prone position is strongly recommended if severe ARDS exists. In some patients with moderate to severe disease, higher PEEP may be useful, but will be dependent upon recruitability and the balance between recruitment, overdistension and haemodynamic consequences [2]. These relations render ARDS as an interesting target for physiological simulation since the impact of the intervention may be different depending on the actual patient state.

This engineering challenge is, then, not just a ventilator control issue. An environment that is supportive to the management of patients should link physiologic variables of the patient, ventilator inputs, gas exchange variables, respiratory mechanic and monitoring outputs. Mathematical modelling offers a repeatable way to represent these relationships and computational simulation allows experiments to be conducted on virtual patients under different conditions. Meanwhile, modern monitoring systems are increasingly delivering continuous waveform and numerical data, opening the door to real-time visualization and remote monitoring [3][4].

ARDS Pathophysiology and Heterogeneity

This is the heterogeneity that is relevant for engineering models. An oxygenation and compliance response that is assigned to a single fixed value for every patient will not capture the variation that drives individualized ventilation, but can produce general trends. Useful representation can be made to allow for a representation of respiratory mechanics and gas exchange that varies with severity, without changing the set of controls for the ventilator. It is therefore possible to conveniently represent the mild, moderate and severe virtual state with systematic changes in compliance, oxygen transfer efficiency and other related parameters. It is also important to combine variables, as is reflected in the clinical classification of ARDS. A summary of the degree of oxygenation impairment is given by the $\text{PaO}_2/\text{FiO}_2$ ratio but the interpretation of the degree of oxygenation should be based on the settings of the ventilator, together with the PEEP and the respiratory mechanics. Pulse oximetry provides continuous non-invasive data but is known to have limitations and it is suggested that multiple complementary data can be used in simulation and monitoring [7].

Supportive Mechanical Ventilation and Lung Protection

The major goal of mechanical ventilation in ARDS is to achieve efficient gas exchange without causing ventilator-induced lung injury. The recommended tidal volume is to refer to the tidal volume guideline, which is 4–8 mL/kg of predicted body weight, and keep the plateau pressure less than 30 cmH₂O [8]. The 2024 American Thoracic Society update also reiterates the principles of lung-protective ventilation and personalized approach to moderate-to-severe ARDS management [9].

These variables are coupled variables: tidal volume, PEEP, FiO_2 , respiratory rate and airway pressure.

Decreasing tidal volume will decrease stress and strain and may elevate PaCO_2 unless minute ventilation is changed. PEEP can keep the lungs open and promote oxygenation, but too high a PEEP can lead to overdistention and will affect circulation. FiO_2 directly alters the concentration of O_2 in the inspired air; the effect of FiO_2 on arterial O_2 is determined by the degree of shunting and the amount of functioning lung.

Respiratory mechanics act as a linkage between ventilator inputs and physiologic response. The equation of motion is represented as $P_{\text{aw}}(t) = \text{PEEP} + E \cdot V(t) + R \cdot \dot{V}(t)$ in which P_{aw} is the airway pressure, E is the elastance, V is the volume, R is the resistance and $\dot{V}$ is the flow. Elastance is the reciprocal of compliance. Driving pressure is generally calculated as the difference between the plateau pressure and PEEP and is an essential measure of mechanical load [10].

Physiological Monitoring and Performance Indicators

Monitoring ARDS needs to be done concurrently with consideration of oxygenation, ventilation, and mechanics. PaO_2 is a direct measurement of arterial oxygen tension while SpO_2 continuously estimates haemoglobin saturation which is not invasive. PaCO_2 is a measure of CO_2 elimination. The P/F ratio is the relationship between the arterial O_2 tension and the inspired O_2 concentration, and is a useful tool for characterizing the impairment of oxygenation [11].

Mechanical behaviours are described by respiratory compliance, plateau pressure, PEEP and driving pressure. Waveforms of pressure, flow and volume provide temporal information which cannot be obtained from the stand-alone measurement of numbers. Instead of showing physiological indicators as values that are unrelated, a strong simulation dashboard should reveal the relationships between inputs and outputs [12].

Mathematical Modelling of Respiratory Physiology

Mathematical modelling is a quantitative description of the relationships between ventilator pressure, airflow, lung volume, compliance, resistance, oxygenation and carbon-dioxide elimination. The equation of motion is the basis for describing pressure, volume, flow, resistance and elastance. In more detailed models, more compartments can be used to model differences in lung regions, recruitment and derecruitment, perfusion differences and gas exchange. Computational modelling has a great value when clinical experimentation is limited. An in-silico patient can be subjected to alternative ventilator strategies and/or to different in-silico patients to be subjected to the same strategy. This repeatability is appealing for testing hypotheses and making decisions on research and development in simulation [13].

But, complexity of the model should be proportional to the purpose. A very detailed multiscale model can be used to simulate recruitment and derecruitment as well as the behaviour of the tissues, but may need significant computational resources. However, if it is necessary to have assumptions made explicit, then a compact model might be more appropriate for real-time dashboards. This facilitates a modular design with mechanics, gas exchange and severity being distinct components.

Computational Simulation and Virtual Patients

Research on mechanical ventilation is becoming increasingly relevant the virtual patient concept. Evaluation of ventilation strategies with model-based simulators is possible in a controlled environment. Giosa et al. (2022) discussed the possibilities and limitations of in-silico mechanical-ventilation modelling and highlighted the need for reproducibility and configurability.

There has been more recent work trying to consider the variability of ARDS with increasing sophistication. Dynamic recruitment/derecruitment can be modelled within full lung simulations and computational physiological models can be used to assist in PEEP titration. Digital-twin models are an extension of this idea, combining patient-specific data with physiological models. [14] also compared a physiology-model/digital-twin decision-support system in ARDS with no difference in the primary driving-pressure outcome; however, some physiological measures were improved. This is a demonstration of the potential and significance of having strict model validation of systems [15][16][17][30].

Real-Time Graphical Visualization and Decision Support

Ventilators produce pressure, flow and volume waveforms and monitors measure oxygen saturation and other physiology. Blood-gas analysis provides information on oxygenation and carbon dioxide periodically. These data will still be provided on separate interfaces, requiring clinicians to mentally combine the data.

[18] assessed a real-time visualization system to support data-driven decision making and found that the ventilation strategies implemented for lung protection were enhanced. Visualization in an engineering simulator should show the present status, and the temporal evolution and relationships of the inputs and outputs. Numerical cards, waveform plots, trends and alert logic can then be integrated into one dashboard.

Visualization in a research simulator should not be interpreted as clinical decision automation. It is intended to allow for making the computational state observable, reproducible and interpretable.

Web-Based and Remote Monitoring

Web-based monitoring breaks down the service and client component, allowing monitoring to be more accessible. [19] created a web-based ventilator monitoring system based on central monitoring and mobile apps on remote devices. [20] also created an online tool that provides real-time mechanical-ventilation monitoring and identification of patient-ventilator asynchrony.

These principles can be applied in a simulation environment without connecting to a clinical ventilator. The simulator can simulate physiological data, publish it via a web app, and allow the user to view the state remotely. The outputs of a research simulator must be clearly identified as simulated and the simulator must not suggest that values are obtained from a real patient.

Oxygen Delivery and ICU Device Performance

Supportive respiratory care is basic to delivery of oxygen as inadequate pulmonary oxygen transfer is a hallmark of ARDS. FiO_2 thus plays an important role in clinical management and simulation. But FiO_2 alone is not enough to infer the oxygenation response, because there are other factors that influence the arterial response which are shunt, recruitment, perfusion and ventilation. Pulse oximetry has been widely adopted due to its continuous, non-invasive data. [21] demonstrated the utility of $\text{SpO}_2/\text{FiO}_2$ in the assessment of ARDS in the absence of arterial blood gases, and highlighted key limitations. Biomedical-engineering aspects of device performance are accuracy, stability, responsiveness, alarm behaviour and alarm continuity. These concepts can be simulated by forcing perturbations and specifying performance measure.

Integrated Performance Strategies for ARDS Supportive Management

The literature shows that the greatest engineering challenge is not the development of another stand-alone part, but rather the integration. Physiological goals are set in clinical guidelines, mathematical relationships in respiratory-mechanics research, a virtual patient in computation, a manifestation of the state in visualization and remote access through web technologies.

It can be thought of as a closed computational loop in an integrated architecture. The patient model determines baseline patient characteristics and ARDS severity. The ventilator setting is set by the user. The mechanics module derives pressure, volume and flow. The gas-exchange module computes the distribution of oxygenation and carbon-dioxide behaviour. The numerical solver is used for advancing the state forward in time. Monitoring modules are used to transform the state to indicators and waveforms. Alert logic compares against the predetermined conditions. The result is displayed in the dashboard and the new user input is fed again into the simulation. This architecture directly tackles the limitation of non-integrated systems. Any change in PEEP, for instance, should be passed down the line of the model and may affect end-expiratory pressure, oxygenation and driving pressure. Likewise, a change in tidal volume should affect the volume delivered and the pressure, as per the mechanics' model.

Research Gap and Future Research Directions

Although there has been significant advances, the literature is still fragmented. Physiological models or optimization of ventilators variables are often the focus of mathematical modeling. Real-time visualization studies concentrate on information presentation, and decision support. Web based systems focus on data transmission and remote access. Device studies generally focus on a specific part of the chain of respiratory support devices instead of the entire chain.

The gap is then an integration gap not a technology gap. The ARDS Supportive Management Simulator overcomes this, by integrating the most important components in an object-oriented computational environment. The next steps for future research include more robust validation with clinical and experimental data, the incorporation of patient-specific parameter estimation, a more explicit representation of recruitment/derecruitment, the addition of other respiratory-mechanics indicators, such as mechanical power, and the study of interoperability, uncertainty, cybersecurity, usability and human factors.

CONCLUSION


ARDS supportive management is fundamentally a dynamic systems problem involving interactions among impaired lung physiology, mechanical ventilation, oxygen delivery and continuous monitoring. Current evidence supports lung-protective ventilation and increasingly emphasizes individualized assessment of respiratory mechanics and oxygenation. Mathematical modelling, computational simulation, real-time visualization and web-based monitoring provide complementary technical foundations for integrated research platforms. The literature demonstrates that computational models can provide reproducible virtual patients, visualization systems can improve access to complex respiratory data, and web-based architectures can extend monitoring beyond the bedside. However, these capabilities remain insufficiently integrated into a single ARDS-specific environment. An integrated simulator can bridge this gap by linking patient severity, ventilator inputs, respiratory mechanics, gas exchange, dynamic outputs, waveforms, alerts and remote access. Such a system should be positioned as a biomedical-engineering research and training platform rather than an autonomous clinical decision-maker.

Table 1. Summary of Key Literature and Relevance to the Proposed Integrated Platform

Study/Source	Primary contribution	Relevance to integrated simulator	Key limitation/gap
[22]	Evidence-based lung-protective ventilation	Defines tidal-volume and plateau-pressure design constraints	Clinical guideline; not a computational platform
[23]	Updated ATS ARDS management recommendations	Supports contemporary supportive-management logic	Does not integrate software simulation and remote monitoring
[24]	Review of in-silico mechanical ventilation	Establishes modelling opportunities and pitfalls	Highlights need for careful model validation
[25]	Physiology-model/digital-twin decision support	Demonstrates patient-specific computational support	Clinical DSS rather than an open integrated simulator
[26]	Real-time respiratory visualization	Supports dashboard and data-driven monitoring	Focuses mainly on visualization/decision support
[27]	Web-based ventilator monitoring	Supports central and remote access architecture	Monitoring platform rather than ARDS physiology simulator
[28]	Cloud continuous ventilation monitoring	Supports remote respiratory surveillance	Focuses on patient-ventilator asynchrony
[29]	Pulse-oximetry assessment in ARDS	Supports multimodal oxygenation monitoring	Does not provide integrated device-performance simulation

Figure 1. Proposed Integrated Architecture for the ARDS Supportive Management Simulator

Figure 1. Proposed integrated architecture for the ARDS Supportive Management Simulator.



REFERENCES

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000;342:1334–1349.
2. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. *Intensive Care Med* 2012;38: 1573–1582.
3. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. *N Engl J Med* 2017;377:1904–1905.
4. Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. *Lancet* 2022;400:1145–1156.
5. Matthay MA, Arabi Y, Arroliga AC, Bernard G, Bersten AD, Brochard LJ, et al. A new global definition of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2024;209:37–47.
6. Gorman EA, O’Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. *Lancet* 2022;400:1157–1170.
7. Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, et al.; American Thoracic Society, European Society of Intensive Care Medicine, and Society of Critical Care

- Medicine. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2017;195:1253–1263.
8. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. € GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol* 2011;64:380–382.
 9. American Thoracic Society. Policy for management of financial conflicts of interest in the development of ATS Clinical Practice Guidelines. New York: The Society; 2015 [published 2015 Jan 7; accessed 2023 Apr 21]. Available from: <https://www.thoracic.org/statements/documentdevelopment/resources/cpg-specific-coi-policy.pdf>.
 10. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011;64:395–400.
 11. Dinglas VD, Faraone LN, Needham DM. Understanding patient-important outcomes after critical illness: a synthesis of recent qualitative, empirical, and consensus-related studies. *Curr Opin Crit Care* 2018;24:401–409.
 12. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–394.
 13. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336:924–926.
 14. Rochwerg B, Alhazzani W, Jaeschke R. Clinical meaning of the GRADE rules. *Intensive Care Med* 2014;40:877–879.
 15. Qadir N, Bartz RR, Cooter ML, Hough CL, Lanspa MJ, BannerGoodspeed VM, et al.; Severe ARDS: Generating Evidence (SAGE) Study Investigators; Society of Critical Care Medicine's Discovery Network. Variation in early management practices in moderate-to-severe ARDS in the United States: the Severe ARDS: Generating Evidence Study. *Chest* 2021;160:1304–1315.
 16. Lamontagne F, Agarwal A, Rochwerg B, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. *BMJ* 2020; 370:m3379.
 17. Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, et al.; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. *N Engl J Med* 2023;388:1931–1941.
 18. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. *Intensive Care Med* 2021;47: 521–537.
 19. Annane D, Sebille V, Bellissant E; Ger-Inf-05 Study Group. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. *Crit Care Med* 2006;34:22–30.

20. Liu L, Li J, Huang YZ, Liu SQ, Yang CS, Guo FM, et al. [The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency]. *Zhonghua Nei Ke Za Zhi* 2012;51:599–603.
21. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. *Chest* 2007;131:954–963.
22. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 1998;280:159–165.
23. Rezk NA, Ibrahim AM. Effects of methyl prednisolone in early ARDS. *Egypt J Chest Dis Tuberc* 2013;62:167–172.
24. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. *N Engl J Med* 2006;354:1671–1684.
25. Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. *Crit Care* 2016;20:329.
26. Villar J, Ferrando C, Martinez D, Ambros A, Muñoz T, Soler JA, ~ et al.; Dexamethasone in ARDS Network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med* 2020;8:267–276.
27. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. *N Engl J Med* 2020;384:693–704.
28. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al.; Metcovid Team. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. *Clin Infect Dis* 2021;72:e373–e381.
29. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al.; COALITION COVID-19 Brazil III Investigators. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. *JAMA* 2020;324: 1307–1316.
30. Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G, Badi e J, et al.; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. *JAMA* 2020;324:1298–1306.